Asset profile
Zamicastat
Small molecule
Evidence outlook · lead readout
NCT04316143 · Pulmonary Arterial Hypertension
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT04316143: The study was non-randomized, open-label, sequential, and had no placebo or active comparator; 33 patients were enrolled, with only 1, 4, and 17 patients contributing to key pharmacokinetic analyses at 50, 100, and 200 mg. Its primary endpoints were pharmacokinetic surrogate measures, and there was no formal comparative efficacy endpoint to meet or miss.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.